Skip to main content
ArticleOPEN ACCESS

GLP1R agonists: primary cardiovascular prevention and oral administration

Nature Reviews Cardiology
DOI: 10.1038/s41569-019-0232-z
1Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The REWIND, PIONEER 4 and PIONEER 6 trials of GLP1R agonists show the cardiovascular benefits of dulaglutide in patients with diabetes and no previous cardiovascular events and that oral semaglutide is safe and noninferior to subcutaneous injections of liraglutide.

Cite

CITATION STYLE

APA

Lim, G. B. (2019, August 1). GLP1R agonists: primary cardiovascular prevention and oral administration. Nature Reviews Cardiology. Nature Publishing Group. https://doi.org/10.1038/s41569-019-0232-z

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free